Latest Breaking News On - Uggest atai nl0015000dx5 - Page 1 : comparemela.com

RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia.GRX-917: Presented PD data from the completed Phase 1 study, which suggest the. | May 11, 2023

Allan malievskyDeuterated etifoxineStephen bardinSociety for biological psychiatryDevelopment rd expensesLife sciencesExchange commissionSecurities exchangeHercules capital incCognitive impairment associatedPivotal trialFlorian brandPipeline recent highlightsPro cognitive neuromodulatorCognitive batteryAnxiety disorders